Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024

Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance

Kwality Pharmaceuticals receives SFDA GMP approval for 2 units

This certification will open new markets for the Kwality Pharma

Laurus Labs invests in Laurus Bio

Merck Life Science India ink MoU with GeNext Genomics

Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

Prime Minister launches expansion of health coverage for citizens of and above 70 years

Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age

Strides Pharma's CDMO arm OneSource raises Rs. 801 crore in pre-listing round

The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion

Strides secures shareholders approval for OneSource CDMO

The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE

Health Ministry approves introduction of new shorter, more efficacious treatment regimen for drug-resistant TB

The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure

India's bioeconomy to reach US $300 billion by 2030: Dr. Jitendra Singh

The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come